Obesity Drugs Are a Potential $100 Billion Opportunity by 2030, Goldman Sachs Analysts Say
- Lilly, Novo Nordisk may control 80% of obesity market in 2030
- Shares of both have surged on potential for weight-loss drugs
This article is for subscribers only.
As the buzz surrounding weight-loss drugs gets ever louder, analysts at Goldman Sachs Group Inc. predict the market for such products could reach $100 billion by 2030, with Eli Lilly & Co. and Novo Nordisk A/S leading the pack.
Goldman’s prediction is the latest in a series to foresee triple-digit billion sales in the anti-obesity market, fueled in particular by recent clinical trial results showing that Novo’s Wegovy reduced not just weight but also the risk of heart attacks and strokes.